Key Publications

Hepatitis C virus (HCV) is a major public health threat in the UK. These reports summarise the scale of the problem and are intended to support focused action.

This bulletin presents the latest figures from the Office for National Statistics (ONS) on deaths related to drug poisoning (involving both legal and illegal drugs) and drug misuse (involving illegal drugs) in England and Wales.

Harm Reduction Coalition invited experts from several countries to share their various SIF models, planning and policy development process, implementation challenges, and evaluation results. This report is a summary of the proceedings of the consultation.

Many of the most vulnerable people are not well served by existing models of treatment. So we need new ways of engaging these people in services that can save their lives. The need for drug consumption rooms is urgent.

Safer drug consumption facilities (SDCFs) are clean, hygienic environments where people can consume drugs, obtained elsewhere, under the supervision of trained health professionals.

Supervised drug consumption facilities, where illicit drugs can be used under the supervision of trained staff, have been operating in Europe for the last three decades.

This resource is intended for harm reduction service providers with limited experience of working with children and young people who inject drugs. It sets out a process that you can go through quickly, with little cost, to prepare for work with children and young people who are under 18.

Preventing the transmission of blood-borne viruses (BBV) such as HIV, hepatitis B and hepatitis C among people who inject drugs can have wide-reaching benefits: reducing health harms to individuals and subsequent costs to society.

The uk government has released the details of the changes being made in UK law to ease distribution of naloxone to people who are at risk of opiate overdose (changes will be happening Oct 2015).

These guidelines produced by the World Health Organisation aim to reduce the number of deaths from opioid overdose by providing evidence-based recommendations on the availability of naloxone for people likely to witness an opioid overdose along with advice on the resuscitation and post-resuscitation care of opioid overdose in the community.